Evidence map›Paper›PMID 25918951›Full record

ArticleAmerican journal of respiratory and critical care medicine2015

Increased Mutagen Sensitivity and DNA Damage in Pulmonary Arterial Hypertension.

Chiara Federici, Kylie M Drake, Christina M Rigelsky, Lauren N McNelly, Sirena L Meade, Suzy A A Comhair, Serpil C Erzurum, Micheala A Aldred

2 registry-linked trialsAbstract read
In one paragraph

Article in American journal of respiratory and critical care medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
7.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03251872 early_phase1terminatednot on this mapstarted 2018, after this paper: background citation

Olaparib for Pulmonary Arterial Hypertension: a Pilot Clinical Study

TypeinterventionalSponsorLaval UniversityRan2018 to 2019Enrolled6ConditionsPulmonary Arterial HypertensionArmsOlaparib
NCT03655704 early_phase1completednot on this mapstarted 2019, after this paper: background citation

Apabetalone for Pulmonary Arterial Hypertension: a Pilot Study

TypeinterventionalSponsorSteeve ProvencherRan2019 to 2021Enrolled7ConditionsPulmonary Arterial HypertensionArmsApabetalone
3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 100 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. New Drugs and Therapies in Pulmonary Arterial Hypertension.International journal of molecular sciences · 2023
    Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 3 countries.

Chiara Federici1 Genomic Medicine Institute and.
Kylie M Drake1 Genomic Medicine Institute and.ORCID http://orcid.org/0000-0003-1405-4694
Christina M Rigelsky1 Genomic Medicine Institute and.
Lauren N McNelly1 Genomic Medicine Institute and.
Sirena L Meade1 Genomic Medicine Institute and.
Suzy A A Comhair2 Department of Pathobiology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.
Serpil C Erzurum2 Department of Pathobiology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.
Micheala A Aldred1 Genomic Medicine Institute and.ORCID http://orcid.org/0000-0002-7390-9181
National Institute of Genomic Medicine · MXCleveland Clinic Lerner College of Medicine · US

Funding

Pulmonary Hypertension Breakthrough InitiativeR24HL123767 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI ALDRED, MICHEALA A, ERZURUM, SERPIL C. · 2014 to 2017
$10.1M
NITRIC OXIDE PRODUCTION AND REACTIONS IN THE LUNGR01HL060917 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI Serpil C. Erzurum · 1999 to 2026
$6.3M
Airway redox biochemistry as a deteriminant of asthma phenotype during adolescen*U10HL109250 · NHLBI · UNIVERSITY OF VIRGINIA · PI ERZURUM, SERPIL C., GASTON, BENJAMIN · 2011 to 2016
$4.2M
Nitric Oxide in Pulmonary HypertensionR37HL060917 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI ERZURUM, SERPIL C. · 2009 to 2018
$3.9M
Pulmonary Vascular-Right Ventricular Axis Research ProgramR01HL115008 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI ERZURUM, SERPIL C., PRASAD, SATHYAMANGLA V · 2012 to 2016
$3.1M
Germline and Somatic Genetic Changes in Pulmonary Arterial HypertensionR01HL098199 · NHLBI · INDIANA UNIVERSITY INDIANAPOLIS · PI ALDRED, MICHEALA A · 2010 to 2017
$2.3M
Role of the X-chromosome in Pulmonary Arterial HypertensionR03HL110831 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI ALDRED, MICHEALA A · 2011 to 2012
$157k
NHLBI NIH HHS R01 HL098199NHLBI NIH HHS R01HL098199NHLBI NIH HHS R01 HL115008NHLBI NIH HHS R01HL115008NHLBI NIH HHS R03 HL110831NHLBI NIH HHS R03HL110831NHLBI NIH HHS R24 HL123767NHLBI NIH HHS R37 HL060917NHLBI NIH HHS RC37HL60917NHLBI NIH HHS U10 HL109250
6 · The paper itself

Abstract

rationalePulmonary arterial hypertension (PAH) is a serious lung condition characterized by vascular remodeling in the precapillary pulmonary arterioles. We and others have demonstrated chromosomal abnormalities and increased DNA damage in PAH lung vascular cells, but their timing and role in disease pathogenesis is unknown.

objectivesWe hypothesized that if DNA damage predates PAH, it might be an intrinsic cell property that is present outside the diseased lung.

methodsWe measured DNA damage, mutagen sensitivity, and reactive oxygen species (ROS) in lung and blood cells from patients with Group 1 PAH, their relatives, and unrelated control subjects. MEASUREMENTS AND MAIN

resultsBaseline DNA damage was significantly elevated in PAH, both in pulmonary artery endothelial cells (P < 0.05) and peripheral blood mononuclear cells (PBMC) (P < 0.001). Remarkably, PBMC from unaffected relatives showed similar increases, indicating this is not related to PAH treatments. ROS levels were also higher (P < 0.01). DNA damage correlated with ROS production and was suppressed by antioxidants (P < 0.001). PBMC from patients and relatives also showed markedly increased sensitivity to two chemotherapeutic drugs, bleomycin and etoposide (P < 0.001). Results were consistent across idiopathic, heritable, and associated PAH groups.

conclusionsLevels of baseline and mutagen-induced DNA damage are intrinsically higher in PAH cells. Similar results in PBMC from unaffected relatives suggest this may be a genetically determined trait that predates disease onset and may act as a risk factor contributing to lung vascular remodeling following endothelial cell injury. Further studies are required to fully characterize mutagen sensitivity, which could have important implications for clinical management.

Indexed as

Chromosome AberrationsDNA DamageHumansHypertension, PulmonaryLungPulmonary ArteryReactive Oxygen SpeciesReactive Oxygen SpeciesBMPR2DNA damagegenetic susceptibilityreactive oxygen species

Identifiers

PMID25918951
PMCPMC4532823
OpenAlexW2126150920

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.